Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.

Weil-Hillman G, Voss SD, Fisch P, Schell K, Hank JA, Sosman JA, Sugamura K, Sondel PM
Cancer Res. 1990 50 (9): 2683-91

PMID: 1691679

MeSH Terms (12)

Antibodies, Monoclonal Antigens, Differentiation, T-Lymphocyte CD3 Complex CD56 Antigen Dose-Response Relationship, Drug Humans Interleukin-2 Killer Cells, Lymphokine-Activated Lymphocyte Activation Phenotype Receptors, Antigen, T-Cell Receptors, Interleukin-2

Connections (1)

This publication is referenced by other Labnodes entities: